ReviewCardiovascular endocrinology2017
Cardiovascular risk assessment and screening in diabetes.
Review in Cardiovascular endocrinology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Immune Checkpoint Restoration as a Therapeutic Strategy to Halt Diabetes-Driven Atherosclerosis.Biology · 2025Review
- Effectiveness of a nurse-led management intervention on systolic blood pressure among type 2 diabetes patients in Uganda: a cluster randomized trial.Clinical diabetes and endocrinology · 2024Article
- Cardiovascular Risk Among Patients with Controlled and Uncontrolled Type 2 Diabetes: A Sub-Cohort Analysis from the Heart Health Promotion (HHP) Study.International journal of general medicine · 2023Article
- Assessment of Different Risk Factors Among Adult Cardiac Patients at a Single Cardiac Center in Saudi Arabia.Cureus · 2020Article
- The Evolving Cardiovascular Disease Risk Scores for Persons with Diabetes Mellitus.Current cardiology reports · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes used to be considered as a coronary heart disease equivalence and universally classified high cardiovascular risk population. However increasing epidemiological evidence now indicates the heterogeneity of risk among the diabetic patients and imposes animportance of stratifying those with relative low-risk from high-risk ones. Despite the existing risk assessment tools, current cardivoascualr disease prevention guidelines fail to provide more detailed stratification strategies for patient with diabetes and expose them to either overtreatment or undertreatment. On the other hand, various screening modality, including novel biomarkers and subclinical asthrosclerosis scanning, including coronary calcium scanning, carotid intima-media thickness, myocardial perfusion imaging and coronary computed tomography angiography, have provided very promising usage is risk stratification. With better developed test techniques and more extensive evidence, these modalities may serve in standardized screening algorithm to improve the cardiovascular risk assessment of patients with diabetes and better instruct their individualized preventive therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.